Brief: CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
23/08/2024 13:06
Aug 23 (Reuters) - Hyundai Feed Inc 016790.KQ :
* CANARIABIO INC ANNOUNCES ENROLLMENT COMPLETION OF
RANDOMIZED
PHASE 2 STUDY OF OREGOVOMAB IN COMBINATION WITH CHEMOTHERAPY AS
NEO-ADJUVANT TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER
Source text for Eikon: ID:nPn1PDbQSa
Further company coverage: 016790.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyundai Feed
See all newsBrief: CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
Brief: Canariabio Achieves Significant Milestone With FDA's Orphan Drug Designation For Mab-Ar20.5 Targeting Pancreatic Cancer